Picozzi, Vincent J <br/><br/>
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Sep 2015 
 - 1857-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2015.06.119  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--immunology<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Chemotherapy, Adjuvant<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Mucins--immunology<br/>Pancreatic Neoplasms--immunology<br/>Radioimmunotherapy--adverse effects<br/>Radiopharmaceuticals--adverse effects<br/>Remission Induction<br/>Thrombocytopenia--chemically induced<br/>Time Factors<br/>Treatment Outcome<br/>United States<br/>Yttrium Radioisotopes--adverse effects<br/>Gemcitabine